Abstract
The development of colloidal systems (liposomes, nanoparticles) as efficient drug carriers is limited by their distribution within the organism. It is now well established that after intravenous administration these particles are rapidly opsonized by plasma proteins. These adsorbed proteins promote recognition and uptake by cells of the mononuclear phagocyte system (MPS), particularly the Küpffer cells of the liver, but also spleen and bone-marrow macrophages (Puisieux et al., 1994). Activation of complement, especially by the alternative pathway, plays an important role in the processes of opsonization and phagocytosis. If colloidal drug carrier systems are to remain in the blood compartment for any length of time and deliver their contents to organs other than the MPS, strategies for avoiding opsonization must be developed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allen, T.M. and Chonn, A., 1987, Large unilamellar liposomes with low uptake into the reticulo-endothelial system, FEBS Lett. 223:42.
Allen, T.M., Hansen, C, Martin, F., Redemann, C. and Yau-Young, A., 1991, Liposomes containing synthetic lipids derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo, Biochim. Biophys. Acta 1066:29.
Baker, P., Lint, T., McLeod, B., Behrends, C. and Gewürz, H., 1975, Studies on the inhibition of C5-6-induced lysis (reactive lysis) VI. Modulation of C5-6-induced lysis by polyanions and polycations, J. Immunol. 114:554.
Couvreur, P., Grislain, L., Lenaerts, V., Brasseur, F., Guiot, P., and Biornacki, A., 1986, Biodegradable polymeric nanoparticles as drug carriers for antitumor agents, in: Polymeric Nanoparticles and Microspheres, P. Guiot and P. Couvreur, eds., CRC Press, Boca Raton.
Carreno, M.P., Labarre, D., Jozefonvicz, M. and Kazatchkine, M.D. 1988a, The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives, Molec. Immunol. 25:165.
Carreno, M.P., Maillet, F., Labarre, D., Jozefonvicz, M. and Kazatchkine, M.D. 1988b, Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum, Biomaterials 9:514.
Ekre, H.P., Naparstek, Y., Lider, O., Hydén, P., Hägermark, Ö, Nilsson, T., Vlodavsky, I. and Cohen, I., 1992, Anti-inflammatory effects of heparin and its derivatives inhibition of complement and of lymphocyte migration, in: Heparin and Related Polysaccharides. D.A. Lane, ed., Plenum Press, New York.
Gref, R., Minamitake, Y., Peracchia, M.T., Trubetskoy, V., Torchilin, V. and Langer, R., 1994, Biodegradable long-circulating polymeric nanospheres, Science 263:1600.
Gregoriadis, G., McCormack, B., Wang, Z. and Lifely, R., 1993, Polysialic acids: potential in drug delivery, FEBSLett. 315:271.
Huve P., 1994, Comprendre et éviter la capture des nanoparticules de poly (acide-lactique) par le système des phagocytes mononucléaires, Ph.D. Thesis, Université Paris-Sud, Sci. Pharm.
Illum, L., Davis, S.S., Wilson, C.G., Thomas, N.W., Firer, M. And Hardy, J.G., 1982, Blood clearance and organ disposition of intravenously administered colloidal particles: the effects of particle size, nature and shape, Int. J. Pharm. 12:135.
Jeon, S.I., Lee, J.H., Andrade, J.D. and De Germes, P.G., 1991, Protein-surface interactions in the presence of polyethylene oxide; 1. Simplified theory, J. Colloid Interf. Sci. 142:149.
Kazatchkine, M.D., Fearon, D., Silbert, J. and Austen, K., 1979, Surface-associated heparin inhibits zymosan-induced activation of the human alternative pathway by augmenting the regulatory action of the control proteins on particle-bound C3b, J. Exp. Med. 150:1202.
Kazatchkine, M.D., Fearon, D., Metcalfe, D., Rosenberg, R. and Austen, K., 1981, Structural determinants of the capacity of heparin to inhibit the formation of the amplification C3 convertase. J. Clin. Invest. 67:223.
Labarre, D.J., 1990, Heparin-like polymer surfaces: control of coagulation and complement activation by insoluble functionalized polymers, Int. J. Artif Organs 13:651.
Larsson, R., Selén, G., Björklund, H. and Fagerholm, P., 1989, Intraocular PMMA lenses modified with surface-immobilized heparin: evaluation of biocompatibility in vitro and in vivo. Biomaterials 10:511.
Laurell, C.B., 1966, Quantitative estimation of proteins by electrophoresis in agarose gels containing antibodies, Anal. Biochem. 15:45.
Linhardt, R., Rice, K., Kim, Y., Engelken, J. and Weiler, J., 1988, Homogeneous, structurally defined heparinoligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro, J. Biol. Chem. 263:13090.
Maillet, F., Kazatchkine, M.D., Glotz, D., Fischer, E. and Rowe, M., 1983, Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b, Molec. Immunol. 20: 1401.
Maillet, F., Petitou, M., Choay, J. and Kazatchkine, M.D. 1988, Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule, Molec. Immunol. 25:917.
Maillet, F. and Kazatchkine, M.D. (1991) Specific antibodies enhance alternative complement pathway activation by cuprophane, Nephrol. Dial. Transplant. 6:193.
Marconi, W., Benvenuti, F. and Piozzi, A., 1997, Covalent bonding of heparin to a vinyl copolymer for biomédical applications, Biomaterials 18:885.
Mayer, M.M., 1961, Complement and complement fixation, in: Experimental Immunochemistry, EA. Kabat and M.M. Mayer, eds., 2nd Edn, Thomas, Springfield.
Nilsson, U.R., Storm, K.E., Elwing, H. and Nilsson, B., 1993, Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface, Mol. Immunol. 30:211.
Olivier J.C., Vauthier, C, Tarverna, M., Puisieux, F., Ferrier, D. and Couvreur, P., 1996, Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum, J. Control. Rel. 40:157.
Pangburn, M., Atkinson, M. and Meri, S., 1991, Localization of the heparin-binding site on complement factor H, J. Biol. Chem. 266:16847.
Patton, W.A. II, Granzow, CA., Getts, L.A., Thomas, S.C., Zotter, L.M., Gunzel, K.A. and Lowe-Krentz, L.J., 1995, Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells, Biochem. J. 311:461.
Pekna, M., Larsson, R., Formgren, B., Nilsson, U.R. and Nilsson, B., 1993, Complement activation by polymethylmethacrylate minimized by end-point heparin attachment, Biomaterials 14:189.
Puisieux, F., Barratt, G., Couarraze, G., Couvreur, P., Devisssaguet, J.P., Dubernet, C, Fattal, E., Fessi, H., Vauthier, C. and Benita, S., 1994, Polymeric micro-and nanoparticles as drug carriers, in: Polymeric Biomaterials, S. Dumitriu, ed., M. Dekker, New York.
Riesenfeld, J, Olsson, P., Sanchez, J. and Molines, E. Surface modification with functionally active heparin. Med. Dev. Tech. March 1995:24.
Sahu, A. and Pangburn, M. K., 1993, Identification of multiple sites of interaction between heparin and the complement system. Molec. Immunol. 30:679.
Sim, E., Parker, K.E. and Jones, A., 1993, Nucleophilic compounds acting on C3 and C4 in: Activators and Inhibitors of Complement, Sim R.B. Ed., Kluwer Academic Publishers, Dordrecht.
Tröster, S.D. and Kreuter, J., 1992, Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles, J. Microencap. 9:19.
Verrecchia, T., Spenlehauer G., Bazile, D.V., Murry-Brelier, A., Archimbaud, Y. and Veillard, M, 1995, Non-stealth (poly(lactic acid / albumin)) and stealth (poly (lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers, J. Control. Rel. 36:49.
Vittaz, M., Bazile, D., Spenlehauer, G., Verracchia, T., Veillard, M., Puisieux, F. and Labarre, D., 1996, Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators, Biomaterials 17:1575.
Weiler, J. and Linhardt, R., 1989, Comparison of the activity of polyanions and polycations on the classical and alternative pathways of complement. Immunopharmacology 17:65.
Weiler, J., Yurt, R., Fearon, D. and Austen, K., 1978, Modulation of the formation of the amplification convertase of complement C3bBb, by native and commercial heparin, J. Exp. Med. 147:409.
Weiler, J., Edens, R., Linhardt, R. and Kapelanski, D., 1992, Heparin and modified heparin inhibit complement activation in vivo, J. Immunol. 148:3210.
Woodle, M.C. and Lasic, D.D., 1992, Sterically stabilized liposomes, Biochim. Biophys. Acta 1113:171.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Passirani, C., Barratt, G., Devissaguet, JP., Labarre, D. (1998). Development of a New Class of Nanoparticles which Avoid Phagocytosis by Inhibiting Complement Activation. In: Gregoriadis, G., McCormack, B. (eds) Targeting of Drugs 6. NATO ASI Series, vol 300. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0127-9_21
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0127-9_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0129-3
Online ISBN: 978-1-4899-0127-9
eBook Packages: Springer Book Archive